South & Central America Pharmacokinetics Services Market Forecast to 2031 - Regional Analysis - by Drug Type, Service Type, Therapeutic Application, and End User

Description

List of Tables

The South & Central America pharmacokinetics services market was valued at US$ 40.03 million in 2023 and is expected to reach US$ 68.81 million by 2031; it is estimated to register a CAGR of 7.0% from 2023 to 2031.

Outsourcing of Pharmacokinetics Services to CROs Fuel South & Central America Pharmacokinetics Services Market

Outsourcing pharmacokinetics services to contract research organizations (CROs) offers several advantages to drug manufacturers and sponsors. They can operate cost-effectively by opting for these services. Moreover, they can focus on working flexibly and bringing scalability to their core operations, alongside achieving fast turnaround time. Outsourcing helps pharmaceutical companies to focus on product commercialization while implementing measures for capacity building, cost reduction, and data management. The drug discovery process is complex, and any error or false result can lead to significant costs and delay the process. CROs employ experienced scientists and researchers who hold expertise in pharmacokinetics and other fields. Thus, they provide pharma companies with access to their expertise, thereby eliminating the need to invest in hiring such skilled workforces or providing extra training to build them. Therefore, small companies with promising drug candidates but limited resources and large companies involved in diversifying their operations are opting for clinical research services provided by well-organized CROs, which bolsters the pharmacokinetics services market.

South & Central America Pharmacokinetics Services Market Overview

Brazil is a major destination for clinical trials. According to Clinical Trials Arena, in 2021, Brazil accounted for 1.7% of the global clinical trials activity. In July 2022, Boston CRO acquired Instituto Brasil de Pesquisa Clinica (IBPClin), based in Rio de Janeiro, as the first step toward the implementation of its decentralized clinical trial delivery model in Latin America. It claims to have conducted more than 160 industry-sponsored research studies, enrolling more than 7,000 participants across 12 Brazilian states. IBPClin is the largest research center in South America. In March 2020, the Fiocruz Foundation built a new hospital center with a commitment to invest in clinical trials supported by the World Health Organization (WHO). The new hospital was set to host the Solidarity clinical trial led by Fiocruz in Brazil, the initiative implemented in 18 hospitals in 12 states of Brazil with the support of the Department of Science and Technology of the Ministry of Health and coordinated by INI/Fiocruz. Thus, such initiatives taken for the development of clinical research boost the growth of pharmacokinetics services market in Brazil.

South & Central America Pharmacokinetics Services Market Revenue and Forecast to 2031 (US$ Million)

South & Central America Pharmacokinetics Services Market Segmentation

The South & Central America pharmacokinetics services market is categorized into drug type, service type, therapeutic application, end user, and country.

Based on drug type, the South & Central America pharmacokinetics services market is segmented small molecule, large molecule, and vaccines. The small molecule segment held the largest market share in 2023.

In terms of service type, the South & Central America pharmacokinetics services market is categorized into pre-clinical ADME and human studies, PK/PD analysis and reporting, dosing simulations, risk analysis, and others. The pre-clinical ADME and human studies segment held the largest market share in 2023.

By therapeutic application, the South & Central America pharmacokinetics services market is segmented into oncology, infectious diseases, neurological disorders, autoimmune diseases, gynaecological disorders, cardiovascular diseases, respiratory disorders, and others. The oncology segment held the largest market share in 2023.

By end user, the South & Central America pharmacokinetics services market is segmented into pharmaceutical and biotechnology companies, contract research organization, and others. The contract research organization segment held the largest market share in 2023.

By country, the South & Central America pharmacokinetics services market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America pharmacokinetics services market share in 2023.

Charles River Laboratories International Inc; Eurofins Scientific SE; Certara Inc.; Parexel International Corp; Thermo Fisher Scientific Inc.; Allucent; PACIFIC BIOLABS; and SGS SA are some of the leading companies operating in the South & Central America pharmacokinetics services market.

Product Code: BMIRE00030946

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. South & Central America Pharmacokinetics Services Market - Key Market Dynamics

4.1 Market Drivers
- 4.1.1 Rising Prevalence of Chronic and Infectious Diseases
- 4.1.2 Expanding Range of Application of Pharmacokinetic Studies
- 4.1.3 Outsourcing of Pharmacokinetics Services to CROs
4.2 Market Restraints
- 4.2.1 Limited Reach of Pharmacokinetics Service Providers in Emerging Countries
4.3 Market Opportunities
- 4.3.1 Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics
4.4 Future Trend
- 4.4.1 Increasing Adoption of Big Data Analytics in Pharmacokinetics Services
4.5 Impact of Drivers and Restraints:

5. Pharmacokinetics Services Market - South & Central America Analysis

5.1 South & Central America Pharmacokinetics Services Market Overview
5.2 South & Central America Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031

6. South & Central America Pharmacokinetics Services Market Analysis - by Drug Type

6.1 Overview
6.2 Small Molecule
- 6.2.1 Overview
- 6.2.2 Small Molecule: South & Central America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
6.3 Large Molecule
- 6.3.1 Overview
- 6.3.2 Large Molecule: South & Central America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
6.4 Vaccines
- 6.4.1 Overview
- 6.4.2 Vaccines: South & Central America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

7. South & Central America Pharmacokinetics Services Market Analysis - by Service Type

7.1 Overview
7.2 Pre-Clinical ADME and Human Studies
- 7.2.1 Overview
- 7.2.2 Pre-Clinical ADME and Human Studies: South & Central America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.3 PK/PD Analysis and Reporting
- 7.3.1 Overview
- 7.3.2 PK/PD Analysis and Reporting: South & Central America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Dosing Simulations
- 7.4.1 Overview
- 7.4.2 Dosing Simulations: South & Central America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.5 Risk Analysis
- 7.5.1 Overview
- 7.5.2 Risk Analysis: South & Central America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.6 Others
- 7.6.1 Overview
- 7.6.2 Others: South & Central America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8. South & Central America Pharmacokinetics Services Market Analysis - by Therapeutic Application

8.1 Oncology
- 8.1.1 Overview
- 8.1.2 Oncology: South & Central America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Infectious Diseases
- 8.2.1 Overview
- 8.2.2 Infectious Diseases: South & Central America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Neurological Disorders
- 8.3.1 Overview
- 8.3.2 Neurological Disorders: South & Central America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Autoimmune Diseases
- 8.4.1 Overview
- 8.4.2 Autoimmune Diseases: South & Central America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.5 Gynecological Disorders
- 8.5.1 Overview
- 8.5.2 Gynecological Disorders: South & Central America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.6 Cardiovascular Diseases
- 8.6.1 Overview
- 8.6.2 Cardiovascular Diseases: South & Central America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.7 Respiratory Disorders
- 8.7.1 Overview
- 8.7.2 Respiratory Disorders: South & Central America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.8 Others
- 8.8.1 Overview
- 8.8.2 Others: South & Central America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

9. South & Central America Pharmacokinetics Services Market Analysis - by End User

9.1 Pharmaceutical and Biotechnology Companies
- 9.1.1 Overview
- 9.1.2 Pharmaceutical and Biotechnology Companies: South & Central America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Contract Research Organization
- 9.2.1 Overview
- 9.2.2 Contract Research Organization: South & Central America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Others
- 9.3.1 Overview
- 9.3.2 Others: South & Central America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10. South & Central America Pharmacokinetics Services Market - Country Analysis

10.1 South & Central America
- 10.1.1 South & Central America Pharmacokinetics Services Market Breakdown by Countries, 2023 and 2031 (%)
  - 10.1.1.1 Brazil: South & Central America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.1.1.1.1 Overview
    - 10.1.1.1.2 Brazil: South & Central America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.1.1.1.3 Brazil: South & Central America Pharmacokinetics Services Market Breakdown, by Drug Type
    - 10.1.1.1.4 Brazil: South & Central America Pharmacokinetics Services Market Breakdown, by Service Type
    - 10.1.1.1.5 Brazil: South & Central America Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 10.1.1.1.6 Brazil: South & Central America Pharmacokinetics Services Market Breakdown, by End User
  - 10.1.1.2 Argentina: South & Central America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.1.1.2.1 Overview
    - 10.1.1.2.2 Argentina: South & Central America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.1.1.2.3 Argentina: South & Central America Pharmacokinetics Services Market Breakdown, by Drug Type
    - 10.1.1.2.4 Argentina: South & Central America Pharmacokinetics Services Market Breakdown, by Service Type
    - 10.1.1.2.5 Argentina: South & Central America Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 10.1.1.2.6 Argentina: South & Central America Pharmacokinetics Services Market Breakdown, by End User
  - 10.1.1.3 Rest of South & Central America: South & Central America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.1.1.3.1 Overview
    - 10.1.1.3.2 Rest of South & Central America: South & Central America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.1.1.3.3 Rest of South & Central America: South & Central America Pharmacokinetics Services Market Breakdown, by Drug Type
    - 10.1.1.3.4 Rest of South & Central America: South & Central America Pharmacokinetics Services Market Breakdown, by Service Type
    - 10.1.1.3.5 Rest of South & Central America: South & Central America Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 10.1.1.3.6 Rest of South & Central America: South & Central America Pharmacokinetics Services Market Breakdown, by End User

11. Company Profile

11.1 Charles River Laboratories International Inc
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Eurofins Scientific SE
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Certara Inc.
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Parexel International Corp
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Thermo Fisher Scientific Inc.
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Allucent
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 PACIFIC BIOLABS
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 SGS SA
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments

12. Appendix

12.1 About The Insight Partners
12.2 Glossary of Terms for Pharmacokinetic Services Market